BN Business News
Add your company to Business Communicator →

Business · 01/09/2010Updated: 10/17/2026 · 1 min read

NIH to Grant Exclusive License for Pentosan Polysulfate Prostate Treatment

Summary

The National Institutes of Health is considering granting an exclusive patent license to Swati Spentose Private Limited for the use of pentosan polysulfate to treat benign prostatic hyperplasia, as outlined in U.S. Patent 6,828,309, developed by Dr. Gary Striker.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights

Business insights →